Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs

AVANOS MEDICAL, INC.

2025-Q1 EPS reported $0.14 revenue$167,500,000

Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.
Net income $6.6M ($0.14 diluted EPS) vs $0.5M ($0.01) a year ago; adjusted net income $12.0M ($0.26 adjusted EPS).
SNS segment net sales $101.1M with 8.7% volume growth driven by enteral feeding and neonate solutions.
PM&R segment net sales $56.2M; RFA product sales grew 8.2% from ESENTEC/TRIDENT momentum.
2025 revenue guidance reaffirmed at $665-$685M; adjusted EPS guidance lowered to $0.75-$0.95 due to tariff impacts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.